vs
AtriCure, Inc.（ATRC）与Ecovyst Inc.（ECVT）财务数据对比。点击上方公司名可切换其他公司
Ecovyst Inc.的季度营收约是AtriCure, Inc.的1.4倍（$199.4M vs $141.2M），Ecovyst Inc.同比增速更快（34.0% vs 14.3%），过去两年Ecovyst Inc.的营收复合增速更高（18.7% vs 10.2%）
AtriCure是一家专注于心房颤动及相关心脏病症治疗的医疗设备企业，研发并生产创新外科手术工具与疗法，主要服务北美、欧洲、亚太地区的医院、心脏外科中心及医疗机构，为微创心脏手术提供高效可靠的适配解决方案。
Ecovyst Inc.是一家全球可持续特种材料供应商，主营高性能催化剂与功能性添加剂的研发、生产，产品服务覆盖工业制造、消费品、环保等核心领域，助力全球客户提升运营效率、降低碳排放。
ATRC vs ECVT — 直观对比
营收规模更大
ECVT
是对方的1.4倍
$141.2M
营收增速更快
ECVT
高出19.7%
14.3%
两年增速更快
ECVT
近两年复合增速
10.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $141.2M | $199.4M |
| 净利润 | $108.0K | — |
| 毛利率 | 77.4% | 23.4% |
| 营业利润率 | 23.0% | 10.9% |
| 净利率 | 0.1% | — |
| 营收同比 | 14.3% | 34.0% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.00 | $0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRCECVT
| Q1 26 | $141.2M | — | ||
| Q4 25 | $140.5M | $199.4M | ||
| Q3 25 | $134.3M | $204.9M | ||
| Q2 25 | $136.1M | $176.1M | ||
| Q1 25 | $123.6M | $143.1M | ||
| Q4 24 | $124.3M | $148.9M | ||
| Q3 24 | $115.9M | $153.9M | ||
| Q2 24 | $116.3M | $154.0M |
净利润ATRCECVT
| Q1 26 | $108.0K | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $-267.0K | $-79.3M | ||
| Q2 25 | $-6.2M | $6.0M | ||
| Q1 25 | $-6.7M | $-3.6M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-7.9M | $14.3M | ||
| Q2 24 | $-8.0M | $8.3M |
毛利率ATRCECVT
| Q1 26 | 77.4% | — | ||
| Q4 25 | 75.0% | 23.4% | ||
| Q3 25 | 75.5% | 25.4% | ||
| Q2 25 | 74.5% | 22.8% | ||
| Q1 25 | 74.9% | 13.3% | ||
| Q4 24 | 74.5% | 28.9% | ||
| Q3 24 | 74.9% | 29.3% | ||
| Q2 24 | 74.7% | 27.3% |
营业利润率ATRCECVT
| Q1 26 | 23.0% | — | ||
| Q4 25 | 1.8% | 10.9% | ||
| Q3 25 | 0.2% | 13.8% | ||
| Q2 25 | -4.5% | 9.0% | ||
| Q1 25 | -4.8% | -0.7% | ||
| Q4 24 | -11.7% | 15.1% | ||
| Q3 24 | -6.4% | 17.9% | ||
| Q2 24 | -6.2% | 14.1% |
净利率ATRCECVT
| Q1 26 | 0.1% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | -0.2% | -38.7% | ||
| Q2 25 | -4.5% | 3.4% | ||
| Q1 25 | -5.5% | -2.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | -6.8% | 9.3% | ||
| Q2 24 | -6.9% | 5.4% |
每股收益（稀释后）ATRCECVT
| Q1 26 | $0.00 | — | ||
| Q4 25 | $0.04 | $0.06 | ||
| Q3 25 | $-0.01 | $-0.69 | ||
| Q2 25 | $-0.13 | $0.05 | ||
| Q1 25 | $-0.14 | $-0.03 | ||
| Q4 24 | $-0.33 | $-0.26 | ||
| Q3 24 | $-0.17 | $0.12 | ||
| Q2 24 | $-0.17 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $146.2M | $197.2M |
| 总债务越低越好 | $61.0M | $392.6M |
| 股东权益账面价值 | $491.7M | $603.4M |
| 总资产 | $644.0M | $1.3B |
| 负债/权益比越低杠杆越低 | 0.12× | 0.65× |
8季度趋势，按日历期对齐
现金及短期投资ATRCECVT
| Q1 26 | $146.2M | — | ||
| Q4 25 | $167.4M | $197.2M | ||
| Q3 25 | $147.9M | $82.0M | ||
| Q2 25 | $117.8M | $69.6M | ||
| Q1 25 | $99.9M | $127.5M | ||
| Q4 24 | $122.7M | $131.4M | ||
| Q3 24 | $130.3M | $123.5M | ||
| Q2 24 | $114.0M | $83.3M |
总债务ATRCECVT
| Q1 26 | $61.0M | — | ||
| Q4 25 | — | $392.6M | ||
| Q3 25 | $61.9M | $854.8M | ||
| Q2 25 | $61.9M | $856.6M | ||
| Q1 25 | $61.9M | $859.0M | ||
| Q4 24 | — | $860.8M | ||
| Q3 24 | $61.9M | $862.7M | ||
| Q2 24 | $61.9M | $862.4M |
股东权益ATRCECVT
| Q1 26 | $491.7M | — | ||
| Q4 25 | $491.9M | $603.4M | ||
| Q3 25 | $476.5M | $607.9M | ||
| Q2 25 | $464.5M | $692.4M | ||
| Q1 25 | $454.6M | $698.7M | ||
| Q4 24 | $461.0M | $700.5M | ||
| Q3 24 | $465.0M | $729.4M | ||
| Q2 24 | $462.1M | $717.3M |
总资产ATRCECVT
| Q1 26 | $644.0M | — | ||
| Q4 25 | $654.2M | $1.3B | ||
| Q3 25 | $635.4M | $1.7B | ||
| Q2 25 | $608.8M | $1.8B | ||
| Q1 25 | $591.6M | $1.8B | ||
| Q4 24 | $609.3M | $1.8B | ||
| Q3 24 | $615.1M | $1.8B | ||
| Q2 24 | $597.3M | $1.8B |
负债/权益比ATRCECVT
| Q1 26 | 0.12× | — | ||
| Q4 25 | — | 0.65× | ||
| Q3 25 | 0.13× | 1.41× | ||
| Q2 25 | 0.13× | 1.24× | ||
| Q1 25 | 0.14× | 1.23× | ||
| Q4 24 | — | 1.23× | ||
| Q3 24 | 0.13× | 1.18× | ||
| Q2 24 | 0.13× | 1.20× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $41.8M |
| 自由现金流经营现金流 - 资本支出 | — | $22.9M |
| 自由现金流率自由现金流/营收 | — | 11.5% |
| 资本支出强度资本支出/营收 | — | 9.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $69.9M |
8季度趋势，按日历期对齐
经营现金流ATRCECVT
| Q1 26 | — | — | ||
| Q4 25 | $20.0M | $41.8M | ||
| Q3 25 | $26.7M | $55.3M | ||
| Q2 25 | $21.6M | $33.0M | ||
| Q1 25 | $-11.0M | $10.3M | ||
| Q4 24 | $5.8M | $43.5M | ||
| Q3 24 | $20.0M | $59.9M | ||
| Q2 24 | $7.4M | $10.0M |
自由现金流ATRCECVT
| Q1 26 | — | — | ||
| Q4 25 | $18.4M | $22.9M | ||
| Q3 25 | $24.1M | $53.2M | ||
| Q2 25 | $19.0M | $7.8M | ||
| Q1 25 | $-13.2M | $-14.0M | ||
| Q4 24 | $3.1M | $30.9M | ||
| Q3 24 | $16.4M | $53.6M | ||
| Q2 24 | $5.0M | $-9.3M |
自由现金流率ATRCECVT
| Q1 26 | — | — | ||
| Q4 25 | 13.1% | 11.5% | ||
| Q3 25 | 18.0% | 26.0% | ||
| Q2 25 | 13.9% | 4.4% | ||
| Q1 25 | -10.7% | -9.8% | ||
| Q4 24 | 2.5% | 20.7% | ||
| Q3 24 | 14.1% | 34.9% | ||
| Q2 24 | 4.3% | -6.1% |
资本支出强度ATRCECVT
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | 9.4% | ||
| Q3 25 | 1.9% | 1.0% | ||
| Q2 25 | 2.0% | 14.4% | ||
| Q1 25 | 1.8% | 16.9% | ||
| Q4 24 | 2.2% | 8.5% | ||
| Q3 24 | 3.1% | 4.1% | ||
| Q2 24 | 2.1% | 12.5% |
现金转化率ATRCECVT
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 5.52× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 4.21× | ||
| Q2 24 | — | 1.20× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATRC
| Appendage management | $48.4M | 34% |
| Open ablation | $39.1M | 28% |
| Other | $25.0M | 18% |
| Pain management | $22.4M | 16% |
| Minimally invasive ablation | $6.4M | 5% |
ECVT
| Industrial Mining Automotive | $101.3M | 51% |
| Regeneration And Treatment Services | $90.0M | 45% |
| Other | $8.1M | 4% |
